Search Results Search Sort by RelevanceMost Recent Case and Commentary Nov 2020 Should a Good Risk Manager Worry About Cost and Price Transparency in Health Care? Josh Charles Hyatt, DHSc, MHL, MBE(c) and Stephen L. Newman, MD, MBA Once focused on hospital liability, risk managers now navigate a broader set of enterprise risk management responsibilities. AMA J Ethics. 2020;22(11):E924-932. doi: 10.1001/amajethics.2020.924. Case and Commentary Feb 2019 How Should Clinicians Communicate With Patients About the Roles of Artificially Intelligent Team Members? Daniel Schiff, MS and Jason Borenstein, PhD Clinical applications of AI prompt consideration of how responsibility should be distributed among professionals, tech companies, and others. AMA J Ethics. 2019;21(2):E138-145. doi: 10.1001/amajethics.2019.138. Case and Commentary Feb 2019 Should Watson Be Consulted for a Second Opinion? David D. Luxton, PhD, MS Guidance for organizations using AI tools to diagnose and to develop treatment recommendations can also help clinicians consider risks and benefits. AMA J Ethics. 2019;21(2):E131-137. doi: 10.1001/amajethics.2019.131. Case and Commentary Jan 2020 How Should Public Health Officials Respond When Important Local Rituals Increase Risk of Contagion? Esther Mokuwa, MSc and Paul Richards, PhD, MA During one 2014 Ebola epidemic, arrival of “safe burial” teams was often delayed. Some buried their loved ones themselves, which undermined containment efforts. AMA J Ethics. 2020;22(1):E5-9. doi: 10.1001/amajethics.2020.5. Case and Commentary Aug 2005 Hoping for the Best, Preparing for the Worst: Physician to Patient in Clinical Trial Frederic W. Platt, MD Virtual Mentor. 2005;7(8):541-546. doi: 10.1001/virtualmentor.2005.7.8.ccas2-0508. Case and Commentary Dec 2016 Neuroethics and Disorders of Consciousness: Discerning Brain States in Clinical Practice and Research Joseph J. Fins, MD Which distinctions between minimally conscious states and vegetative states should clinicians consider? AMA J Ethics. 2016;18(12):1182-1191. doi: 10.1001/journalofethics.2016.18.12.ecas2-1612. Case and Commentary Jun 2016 Prescribing “Off-Label”: What Should a Physician Disclose? Katrina Furey, MD and Kirsten Wilkins, MD Off-label prescribing of drugs is appropriate when their use is in the patient’s best interest on the basis of credible, published scientific data. AMA J Ethics. 2016;18(6):587-593. doi: 10.1001/journalofethics.2016.18.6.ecas3-1606. Case and Commentary Nov 2004 Clinical Trials and End-of-Life Decision Making, Commentary 1 David S. Alberts, MD Virtual Mentor. 2004;6(11):477-479. doi: 10.1001/virtualmentor.2004.6.11.ccas1-0411. Case and Commentary Nov 2004 Clinical Trials and End-of-Life Decision Making, Commentary 2 Lucy Godley, MD, PhD Virtual Mentor. 2004;6(11):479-481. doi: 10.1001/virtualmentor.2004.6.11.ccas1-0411. Case and Commentary Nov 2004 Heads or Tails: Randomized Placebo-Controlled Trials, Commentary 1 Charles Weijer, MD, PhD Virtual Mentor. 2004;6(11):482-484. doi: 10.1001/virtualmentor.2004.6.11.ccas2-0411. Pagination Current page 1 Page 2 Page 3 Next page Next › Last page Last »
Case and Commentary Nov 2020 Should a Good Risk Manager Worry About Cost and Price Transparency in Health Care? Josh Charles Hyatt, DHSc, MHL, MBE(c) and Stephen L. Newman, MD, MBA Once focused on hospital liability, risk managers now navigate a broader set of enterprise risk management responsibilities. AMA J Ethics. 2020;22(11):E924-932. doi: 10.1001/amajethics.2020.924.
Case and Commentary Feb 2019 How Should Clinicians Communicate With Patients About the Roles of Artificially Intelligent Team Members? Daniel Schiff, MS and Jason Borenstein, PhD Clinical applications of AI prompt consideration of how responsibility should be distributed among professionals, tech companies, and others. AMA J Ethics. 2019;21(2):E138-145. doi: 10.1001/amajethics.2019.138.
Case and Commentary Feb 2019 Should Watson Be Consulted for a Second Opinion? David D. Luxton, PhD, MS Guidance for organizations using AI tools to diagnose and to develop treatment recommendations can also help clinicians consider risks and benefits. AMA J Ethics. 2019;21(2):E131-137. doi: 10.1001/amajethics.2019.131.
Case and Commentary Jan 2020 How Should Public Health Officials Respond When Important Local Rituals Increase Risk of Contagion? Esther Mokuwa, MSc and Paul Richards, PhD, MA During one 2014 Ebola epidemic, arrival of “safe burial” teams was often delayed. Some buried their loved ones themselves, which undermined containment efforts. AMA J Ethics. 2020;22(1):E5-9. doi: 10.1001/amajethics.2020.5.
Case and Commentary Aug 2005 Hoping for the Best, Preparing for the Worst: Physician to Patient in Clinical Trial Frederic W. Platt, MD Virtual Mentor. 2005;7(8):541-546. doi: 10.1001/virtualmentor.2005.7.8.ccas2-0508.
Case and Commentary Dec 2016 Neuroethics and Disorders of Consciousness: Discerning Brain States in Clinical Practice and Research Joseph J. Fins, MD Which distinctions between minimally conscious states and vegetative states should clinicians consider? AMA J Ethics. 2016;18(12):1182-1191. doi: 10.1001/journalofethics.2016.18.12.ecas2-1612.
Case and Commentary Jun 2016 Prescribing “Off-Label”: What Should a Physician Disclose? Katrina Furey, MD and Kirsten Wilkins, MD Off-label prescribing of drugs is appropriate when their use is in the patient’s best interest on the basis of credible, published scientific data. AMA J Ethics. 2016;18(6):587-593. doi: 10.1001/journalofethics.2016.18.6.ecas3-1606.
Case and Commentary Nov 2004 Clinical Trials and End-of-Life Decision Making, Commentary 1 David S. Alberts, MD Virtual Mentor. 2004;6(11):477-479. doi: 10.1001/virtualmentor.2004.6.11.ccas1-0411.
Case and Commentary Nov 2004 Clinical Trials and End-of-Life Decision Making, Commentary 2 Lucy Godley, MD, PhD Virtual Mentor. 2004;6(11):479-481. doi: 10.1001/virtualmentor.2004.6.11.ccas1-0411.
Case and Commentary Nov 2004 Heads or Tails: Randomized Placebo-Controlled Trials, Commentary 1 Charles Weijer, MD, PhD Virtual Mentor. 2004;6(11):482-484. doi: 10.1001/virtualmentor.2004.6.11.ccas2-0411.